Medical Cannabis Advocacy in South Asia During the 1990s

The legal landscape entering the 1990s

South Asia entered the 1990s under prohibitionist drug law frameworks that had been consolidated in the previous decade. India's Narcotic Drugs and Psychotropic Substances (NDPS) Act, passed in 1985, criminalized the production and sale of cannabis resin (charas) and flowering tops (ganja), while carving out a notable exception for the leaves and seeds — the basis of bhang ^[1] Strong evidence. The Act was the country's belated implementation of obligations under the 1961 UN Single Convention on Narcotic Drugs, which had given signatories 25 years to phase out non-medical cannabis use ^[2] Strong evidence.

Nepal had banned cannabis cultivation and sale in 1976 under US pressure, ending the legal hashish shop era of Kathmandu ^[3] Strong evidence. Pakistan's Control of Narcotic Substances Act came in 1997, formalizing prohibition there Weak / limited. Sri Lanka and Bangladesh maintained colonial-era restrictions, though both preserved limited Ayurvedic exemptions on paper.

The practical effect was that throughout the 1990s, medical cannabis advocacy in South Asia had almost no formal legal opening to push through. Where traditional medicine continued, it did so under the radar of Ayurvedic and Unani pharmacopeias, not under any modern medical-cannabis banner.

Traditional medicine systems as de facto continuity

What looked like advocacy in the 1990s was, more accurately, continuity. Cannabis (vijaya, bhanga) has documented use in classical Ayurvedic texts including the Sharngadhara Samhita (c. 13th–14th century) and Bhavaprakasha (16th century), where preparations like jatiphaladi churna include cannabis as an ingredient ^[4] Strong evidence. The Unani tradition similarly listed qinnab among its materia medica.

India's Central Council for Research in Ayurvedic Sciences (CCRAS) and the Department of AYUSH precursors continued to permit licensed Ayurvedic manufacturers to use cannabis leaf in classical formulations throughout the 1990s, sourced through state excise channels in states like Uttar Pradesh and Rajasthan that retained bhang licensing Weak / limited. This was administrative continuity, not advocacy. There was no organized push to expand medical access, schedule cannabis differently, or run clinical trials.

A persistent online claim is that Indian Ayurvedic associations "lobbied for medical cannabis" during this period. We found no documented evidence of any such organized lobbying campaign in the 1990s No data. The lobbying that did occur was to preserve existing traditional-medicine exemptions, not to create new medical-cannabis pathways.

Academic and harm-reduction voices

The closest thing to advocacy in the 1990s came from a small number of researchers and harm-reduction practitioners. Molly Charles and Dave Bewley-Taylor's later historical work documents that Indian researchers in the late 1980s and 1990s — particularly around the National Institute of Mental Health and Neuro-Sciences (NIMHANS) in Bangalore — published on cannabis use patterns and questioned the public-health framing that justified the NDPS Act ^[5] Weak / limited.

The Indian Hemp Drugs Commission Report of 1894–95, often cited in modern reform arguments, was rediscovered and recirculated by academics during this period; its conclusion that moderate cannabis use caused little harm became a touchstone for later reformers but did not generate a 1990s movement ^[6] Strong evidence.

Internationally, the 1990s saw the founding of organizations like the International Association for Cannabinoid Medicines (1997) in Europe, and California's Proposition 215 in 1996 ^[7] Strong evidence. These developments were noted in South Asian press coverage but did not translate into domestic advocacy organizations during the decade itself.

Myths about the decade

Several myths about 1990s South Asian cannabis advocacy circulate online and deserve direct correction.

Myth: "India had a strong medical cannabis movement in the 1990s." It did not. The country had traditional-medicine continuity and isolated academic critique. The first organized Indian medical cannabis advocacy organizations — such as the Great Legalisation Movement India — were founded in the 2010s, not the 1990s Weak / limited.

Myth: "Nepal quietly tolerated medical cannabis throughout the 1990s." Nepal's 1976 ban was enforced inconsistently, but there was no medical-cannabis carve-out and no organized medical advocacy. Tolerance of personal use during festivals like Maha Shivaratri at Pashupatinath is religious-cultural, not medical Anecdote.

Myth: "Ayurvedic doctors openly prescribed cannabis medicines." Licensed Ayurvedic manufacturers produced classical formulations containing cannabis leaf under state excise rules, but individual prescription of cannabis-forward medicine was rare and legally murky. Most practitioners avoided it Weak / limited.

The honest summary: the 1990s in South Asia were a quiet decade for cannabis policy. Real reform conversations — including India's 2017 reclassification proposals, Nepal's 2020 parliamentary motion to legalize, and Thailand's 2018 medical legalization in the broader region — all came two decades later.

Why the decade still matters

Understanding the 1990s honestly matters because it clarifies where modern South Asian cannabis reform actually comes from. It is not the resumption of a stalled 1990s movement. It is a new movement, drawing on rediscovered colonial-era documents like the Indian Hemp Drugs Commission Report and on the global wave of medical legalization that began with California in 1996 and accelerated in the 2010s.

The traditional-medicine infrastructure that survived the 1990s — bhang licensing in some Indian states, Ayurvedic pharmacopeial recognition, continued cultural acceptance — is the substrate on which any future South Asian medical cannabis framework will likely be built. But the advocacy itself is a 21st-century phenomenon, and rewriting the 1990s as something it wasn't does a disservice to the people doing the actual work today.

Sources

How this page was made